Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Akebia Therapeutics (AKBA) Non Operating Income: 2016-2024

Historic Non Operating Income for Akebia Therapeutics (AKBA) over the last 9 years, with Dec 2024 value amounting to $94,000.

  • Akebia Therapeutics' Non Operating Income rose 41.18% to -$10,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $230,000, marking a year-over-year decrease of 67.00%. This contributed to the annual value of $94,000 for FY2024, which is 89.40% down from last year.
  • Latest data reveals that Akebia Therapeutics reported Non Operating Income of $94,000 as of FY2024, which was down 89.40% from $887,000 recorded in FY2023.
  • Over the past 5 years, Akebia Therapeutics' Non Operating Income peaked at $3.1 million during FY2022, and registered a low of $94,000 during FY2024.
  • Moreover, its 3-year median value for Non Operating Income was $887,000 (2023), whereas its average is $1.4 million.
  • Its Non Operating Income has fluctuated over the past 5 years, first skyrocketed by 333.75% in 2020, then slumped by 89.40% in 2024.
  • Over the past 5 years, Akebia Therapeutics' Non Operating Income (Yearly) stood at $1.9 million in 2020, then surged by 30.06% to $2.4 million in 2021, then surged by 30.32% to $3.1 million in 2022, then tumbled by 71.81% to $887,000 in 2023, then slumped by 89.40% to $94,000 in 2024.